Last reviewed · How we verify
Fibrin adhesive
Fibrin adhesive acts as a biological glue that promotes hemostasis and tissue adhesion by mimicking the final stages of the coagulation cascade to form a stable fibrin clot.
Fibrin adhesive acts as a biological glue that promotes hemostasis and tissue adhesion by mimicking the final stages of the coagulation cascade to form a stable fibrin clot. Used for Surgical hemostasis and tissue adhesion, Wound healing and tissue sealing in surgical applications.
At a glance
| Generic name | Fibrin adhesive |
|---|---|
| Sponsor | Tigenix S.A.U. |
| Drug class | Hemostatic agent / Tissue adhesive |
| Target | Fibrinogen / Thrombin pathway |
| Modality | Small molecule |
| Therapeutic area | Surgery / Hemostasis |
| Phase | Phase 3 |
Mechanism of action
Fibrin adhesive is composed of fibrinogen and thrombin that, when mixed, rapidly polymerize to form a fibrin clot at the site of application. This provides both hemostatic control and mechanical adhesion between tissue surfaces, facilitating wound healing and reducing bleeding during surgical procedures. The adhesive is gradually resorbed as the wound heals.
Approved indications
- Surgical hemostasis and tissue adhesion
- Wound healing and tissue sealing in surgical applications
Common side effects
- Infection at application site
- Allergic reaction
- Thrombosis (rare)
Key clinical trials
- Comparing Clinical Outcomes of the One-step Cartilage Transplantation in Cartilage Defects of the Knee With Conservative Treatment (PHASE3)
- A Trial of Intraoperative Fibrin Sealant on Postoperative Recovery After Total Knee Replacement (PHASE4)
- GATT-Patch Versus TachoSil in Liver Surgery (NA)
- Cost Effectiveness in Alveolar Bone Grafting in Patients With Cleft Lip and Palate (PHASE4)
- Clinical Study of Chondro-Gide® for Large Chondral Lesions in the Knee (NA)
- A Study of REcycled CartiLage Auto/Allo IMplantation to Treat and Repair Focal Hip Cartilage Defects (PHASE1)
- High-Purity Type I Collagen Nerve Wrapping in Peripheral Nerve Procedures: A Prospective Registry (NA)
- Phase 2a Multi-Center Prospective, Randomized Trial to Evaluate the Safety & Efficacy of Topical PEP-TISSEEL for Diabetic Foot Ulcers (DFU) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fibrin adhesive CI brief — competitive landscape report
- Fibrin adhesive updates RSS · CI watch RSS
- Tigenix S.A.U. portfolio CI